Now Recruiting: Clinical Neuroimaging Study on a Rapid-Acting Antidepressant for Major Depressive Disorder

​

We are looking for participants for a clinical research study in Toronto evaluating a novel, rapid-acting, investigational antidepressant for adults with major depressive disorder (MDD).

​

Dextromethorphan-bupropion is a novel antidepressant that is not yet approved by Health Canada, but is already approved by the United States Food and Drug Administration (FDA) as a breakthrough, rapid-acting antidepressant for adults with MDD. 

​

Our trial will offer this treatment for the first time in Canada to eligible participants enrolled in our open-label neuroimaging study. 

​

Our study aims to evaluate how this rapid-acting antidepressant affects brain function - contributing to the advancement of therapeutics for people living with depression. We will also evaluate the effect on key symptoms of depression, including low mood, cognitive function and motivation. 

​

All eligible participants in the trial will receive the active medication during a 2-week treatment period, with additional screening and follow-up visits included. 

 

Eligibility Criteria

You may be eligible for this study if you:

• Are 18 to 65 years old
   

• Are a resident of Canada and located in the Greater Toronto Area (GTA)
   

• Have been diagnosed with Major Depressive Disorder (MDD)
   

• Are currently experiencing symptoms such as depressed mood, low energy, brain fog, or lack of motivation

 

Contact Information

To learn more about the study or to inquire about eligibility, please contact our research team:
📧 research.bcdf@gmail.com